English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219962
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Hydroxicloroquine for pre-exposure prophylaxis for SARS-CoV-2

AuthorsLópez de la Iglesia, Jaime; Cubelos, Naiara; Naveiro, Roi; Montoro Gómez, Marina; González de Haro, Francisco Javier; Ajenjo González, María; Tobal Vicente, Estefanía; Lamuedra Gil de Gómez, María; Nuevo Guisado, María Teresa; Torio Gómez, Isabel; Peñalver Andrada, Ana; Martínez Cao, Nueria; González Figaredo, Paula; Robles García, Carlos; Alvarado Machón, Lidia Anastasia; Lafont Alcalde, Ángeles; Naveiro Rilo, José Cesáreo
KeywordsHydroxychloroquine
Pre-exposure prophylaxis
COVID-19
SARS-CoV-2
Issue Date15-Sep-2020
PublisherMedRxiv
AbstractSARS-CoV-2 infection has a high transmission level. At the present time there is not a specific treatment approved but it is known that, in vitro, chloroquine and hydroxychloroquine can inhibit the coronavirus. Objective: verifying if patients with autoimmune diseases that are on treatment with HCQ have less incidence and severity on COVID-19. Material and methods: this is a retrospective cohort study. The exposed cohort was formed by individuals with autoimmune diseases with HCQ treatment. The control cohort was randomly selected using the Health Card database. To deal with confounding variables and evaluate the effect of HCQ on the incidence and severity of SARS-CoV-2 infection, propensity score matching was used. Risk difference and paired percentage difference between exposed and non-exposed groups was estimated. Results: 919 individuals formed the exposed cohort and 1351 the control cohort. After matching, there were 690 patients on each group. During the time of the study, in the exposed group there were 42 (6.1%) individuals with suspected COVID-19, 12(1.7%) with confirmed COVID-19 and 3(0.4%) were hospitalized. In the control group there were 30(4.3%) individuals with suspected COVID-19, 13(1.9%) with confirmed COVID-19 and 2(0.3%) were hospitalized. The risk difference between each cohort was: 0.017(-0.05-0.04) for suspected COVID-19; -0.014(-0.015-0.012) for confirmed COVID-19 and 0.001(-0.007-0.007) for hospitalized patients. There were not significant differences. Conclusion: there is no difference neither on the incidence nor on the severity of COVID-19 between patients with autoimmune diseases with HCQ treatment and patients that do not take HCQ.
Publisher version (URL)https://doi.org/10.1101/2020.08.31.20185314
URIhttp://hdl.handle.net/10261/219962
DOIhttp://dx.doi.org/10.1101/2020.08.31.20185314
Appears in Collections:(ICMAT) Artículos
(VICYT) Colección Especial COVID-19
Files in This Item:
File Description SizeFormat 
HYDROXICLOROQUINE.pdf103,46 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.